![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Abbvie Inc. North Chicago Us, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Erythromycin, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 1997-001 - Rev 08
This Chemical Type CEP, issued on May 23, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 179 associated with this CEP further emphasizes